The Bull Market Report Examines Presentations From the American Society of Clinical Oncology Annual Meeting


PRINCETON, N.J., May 17, 2005 (PRIMEZONE) -- The Bull Market Report (http://www.bullmarket.com), a long-term growth and income-generating focused investment newsletter, announced today that it has provided to trial and paid subscribers investment analysis of presentations made by major drug companies at the American Society of Clinical Oncology annual meeting, including coverage of Genentech (NYSE:DNA), Pfizer (NYSE:PFE), Amgen (Nasdaq:AMGN) and Medarex (Nasdaq:MEDX).

In the Health Care sector, The Bull Market Report's Recommended List remains overweight and has a buy rating on three stocks, and a holding rating on six stocks.

All paid and trial The Bull Market Report subscribers can now receive immediate access to The Bull Market Report's exclusive daily reports. As a trial or paid subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today: https://www.bullmarket.com/subscribe/?refer=BMR21

The Bull Market Report's investment outlook examines a number of issues, including:


     --  Phase III trial data for Genentech's colon cancer drug
         Avastin when used to fight lung and metastatic breast cancer.

     --  Results of Pfizer's Phase III drug trials for the cancer
         fighting drugs Sutent and AG13736.

     --  Amgen's recent study of its anti-anemia drug Aranesp and the
         company's release of clinical trial data related to its
         Neulasta drug.

     --  Data regarding the efficacy of Medarex's MDX-010 melanoma
         drug.

AND MORE!

Sign up now for a 14-day free trial to The Bull Market and you'll gain instant access to The Bull Market Report's in-depth coverage of the financial services, healthcare, energy, technology and retail, among other, sectors, as well as our Recommended List of over 50 companies, by clicking here: https://www.bullmarket.com/subscribe/?refer=BMR21

Subscribers also receive access to The Bull Market Report's special bonus reports, "Search Sector Outlook" and "Biotech Sector Outlook."

The Bull Market Report is perfect for investors who are serious about building a diversified investment portfolio and are committed to creating long-term wealth.

About The Bull Market Report:

Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The newsletter is ideal for investors looking for long-term growth and income-generating stock investments.

The Bull Market Report's Recommended List includes over 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. As a testament to the durability of its value-focused and fundamentally sound recommendations in both up and down markets, The Bull Market Report is one of the oldest continuously published investment newsletters online. For more information or to sign up now for a free 14-day trial to The Bull Market Report, please visit: https://www.bullmarket.com/subscribe/?refer=BMR21

Note: Indie Research, LLC and the Bull Market editorial staff are not registered investment advisors, broker/dealers, or research analysts/organizations.



            

Contact Data